Lumida
/USPH
⌘K
US Physical Therapy Inc

US Physical Therapy Inc

USPH
$78.72USD+1.30%+1.01 today

MARKET CAP

1.2B

P/E (TTM)

154.4x

FWD P/E

DAY RANGE

$78 – $80

52W RANGE

$58
$94

AI Summary

Stalk
StalkMedium

USPH is in a Stage 2 advancing phase within a confirmed uptrend, marked by higher highs and higher lows above rising EMAs. Price is extended above the 9/20 EMA regime and approaching the 200 DMA with extreme overbought readings, suggesting an imminent pullback. We will stalk for a corrective retracement into the 9/20 EMA and 50 DMA support zones before scaling exposure, consistent with a momentum‐oriented execution style.

  • Analysts forecast 22–25% upside to $88–$102 target prices
  • 7.9% YoY revenue growth driven by outpatient rehabilitation demand
  • P/S ratio of 1.5x exceeds industry average of 1.4x
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

U.S. Physical Therapy, Inc. (NYSE: USPH) is a prominent player in the outpatient physical therapy sector, specializing in industrial injury prevention and rehabilitation services. With a market capitalization of approximately $1.17 billion, USPH operates over 600 clinics across the United States, providing a crucial service amid the growing demand for physical rehabilitation. The company's key focus is on improving patient outcomes through effective physical therapy solutions and has shown notable revenue growth, capturing attention within the healthcare sector.

Bull says

  • Analysts forecast 22–25% upside to $88–$102 target prices
  • 7.9% YoY revenue growth driven by outpatient rehabilitation demand
  • Stock above its 50-day MA with positive momentum
  • Operates 600+ clinics, reinforcing market position in rehab services
  • Attractive earnings yield and solid book-to-price value metrics
  • Manageable debt supports dividends and operational investments

Bear says

  • P/S ratio of 1.5x exceeds industry average of 1.4x
  • Dividend payout at 362% restricts reinvestment capacity
  • Low profitability and negative growth indicators signal cost pressures
  • 3-year returns down 29.3% with negative earnings revisions
  • Lack of hedge fund interest evident from negative 13F ownership
  • Reimbursement and patient volume pressures could erode margins

Investment themes with USPH

Health Care Providers -0.37%

UNH · CVS · HCA

Earnings Call · Q3 2024 · Mgmt. Guidance

Updated 11-09-2025neutral

Transcript signals

Bull points

  • This Q3, our patient visits increased 6% and our visits per clinic per day, which is really our measure of local clinic demand, hit an all-time high for any third quarter with 30.1 visits.
  • This combination drove revenue 9.3% to 142.2 million for Q3 and adjusted EBITDA up 13.4% for the quarter.
  • Revenue this quarter grew approximately 30% compared to Q3 last year, and operating profit was up over 27% in the same period.

Bear points

  • Looking at our salary and related costs as a percentage of revenue, we were able to hold our costs flat year over year at approximately 57.6%, which I feel we can continue to improve upon, especially as we get continued rate left.
  • Physical therapy operating costs were $119.2 million, which includes $3.4 million of closure costs related to the 32 clinics that we closed during the third quarter.
  • predict what the government's going to do is it's been kind of a foolish business
Read full transcript analysis ›